All Oncology News

Breast Oncology Director leads effort to honor luminaries who have helped patients survive

The phase III EPIC trial that was exploring ponatinib in untreated patients with chronic myeloid leukemia has been discontinued following a high occurrence of arterial thrombotic events.

In a phase II clinical trial, the BRAF inhibitor vemurafenib demonstrated antitumor activity in patients with BRAFV600E-mutated papillary thyroid cancer who were either TKI treatment naïve or had received prior TKI treatments.

A meta-analysis of nearly 2000 patients has shown that physical activity may substantially reduce the risk of developing esophageal cancer, especially esophageal adenocarcinoma.

The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs.

An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer.

A VEGF level greater than 0.5 ng/mL in bile aspirated from the pancreas was 93% effective at identifying pancreatic cancer in patients with biliary stricture

Additional investment in and collaboration with ADC Therapeutics

Findings from the first large-scale, genome-wide association study of esophageal adenocarcinoma may lead to new screening tools for those at high risk.

Abiraterone acetate significantly delayed the progression of pain and quality of life deterioration in chemotherapy-naive men with metastatic castration-resistant prostate cancer when taken in combination with prednisone.

A phase III study of the PI3K-delta inhibitor idelalisib in combination with rituximab has been stopped early following a positive interim analysis.

A protein receptor for the "good cholesterol," HDL, may help make breast cancer more aggressive and offer a new target for treating the disease.

The FDA has placed a partial hold on the clinical development of the BCR-ABL inhibitor ponatinib, following the high occurrence of arterial thrombosis in patients treated with the drug.

More than 95 Percent of Advanced Prostate Cancer Patients Receive Multiple Radiation Treatments for Pain Control, Despite Evidence Pointing to Equal Benefit from Single Treatments

Access to Doxil has been inconsistent since mid-2011, when the drug's sole manufacturer announced a voluntary shutdown of production to address significant manufacturing and quality concerns.

Ten cancer programs that have developed pioneering solutions to address the challenges of treating cancer patients have received the Association of Community Cancer Centers' 2013 Innovator Awards.

The National Cancer Institute, part of the National Institutes of Health, has awarded two major grants totaling $26 million to leukemia researchers and physicians at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.

The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) have released updated recommendations for HER2 testing in breast cancer.

Underlying mechanism for increased risk now defined.

Offering free head and neck cancer screenings annually to the community not only has the possibility of early detection, but also the opportunity – particularly in an urban city – to increase a person's understanding of risk factors that cause cancer, according to a new study from Henry Ford Hospital in Detroit.

In response to the growing trend of hospital consolidation, including questions about cancer care decision-making, cost impacts, and delivery of care, the ACCC Institute for the Future of Oncology has released a new white paper that provides perspectives on how these alignments are affecting cancer care providers, cancer programs, and the patients they serve.

Merrimack Pharmaceuticals, Inc. announced today that the last patient has been enrolled in the second cohort of a two-cohort randomized Phase 2 clinical trial of MM-121 in combination with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer.

The investigational immunotherapy MK-3475 has demonstrated an objective response rate of up to 24% in patients with previously treated non-small cell lung cancer

A study of three diverse primary care practices tests the effectiveness of having doctors recommend counseling for colorectal cancer screening. Results found many patients do not follow through with the referral, but for those that do, some change their mind and have a test they might have avoided.

Initiative targets net reduction in annual operating expenses of approximately $2.5 billion by the end of 2015, this includes a plan for new workforce reductions of approximately 8,500 positions, in addition to pending, previously announced reductions.

Two question survey works as well as longer surveys.

Pertuzumab in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer

World-class cancer research and treatment center is the latest to partner with OncLive to promote its research, events, and initiatives

Researchers find that patients are not referred for supportive care services.

Several recently published papers have introduced contradicting findings on the usefulness of BRAF status for predicting the presence of aggressive papillary thyroid cancer.